This research investigates polyploid giant cancer cells, a highly treatment-resistant population responsible for cancer relapse. By studying their structural biology and dependence on lipid metabolism, the work identifies metabolic vulnerabilities that can be targeted alongside chemotherapy, offering a promising strategy to eliminate resistant cancer cells and improve long-term treatment outcomes.

This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research investigates how the structure of comb polymers influences their ability to stabilize materials in applications ranging from fragrances and food products to wastewater treatment and drug delivery. By systematically modifying polymer architecture, the study identifies design rules that enable more effective, affordable, and targeted performance across diverse industrial and medical uses.

This research uses a computational method called MELT to identify hidden allosteric pockets in shape-shifting proteins like BCR–ABL kinase. By targeting these pockets, drugs can stabilize inactive protein states, overcoming resistance caused by protein flexibility and enabling more effective, adaptable strategies for drug discovery.